NCT06030622View on ClinicalTrials.gov

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

April 17, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Pancreatic Cancer Metastatic
Interventions
DRUG

Gemcitabine and C3 (Metformin, Simvastatin, and Digoxin)

Combination treatment of Metformin, Simvastatin and Digoxin with Gemcitabine (Arm 1)

DRUG

C3 (Metformin, Simvastatin, and Digoxin) only

C3 only (Metformin, Simvastatin, and Digoxin) if patients decline Gemcitabine (Arm 2).

Trial Locations (1)

11203

RECRUITING

SUNY Downstate Health Sciences University, Brooklyn

All Listed Sponsors
lead

State University of New York - Downstate Medical Center

OTHER